<p>Neurogene Inc.（納斯達克代碼：NGNE - 獲取免費報告）在覆蓋該股票的七家評級公司中獲得了 “持有” 的共識評級，Marketbeat 報道。一位股票研究分析師對該股票給予了賣出建議，兩位給予了持有建議，四位給予了買入建議。在過去一年中，給予該股票評級的經紀人平均目標價為 42.50 美元。</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
<p>NGNE 一直是多份研究分析師報告的主題。HC Wainwright 在 1 月 13 日的報告中重申了 “買入” 評級，並將 Neurogene 的目標價設定為 70.00 美元。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Neurogene 的 “賣出（d-）” 評級。最後，華爾街禪在 12 月 13 日的研究報告中將 Neurogene 的評級從 “持有” 下調至 “賣出”。</p>
<p><strong>獲取我們對 Neurogene 的最新股票分析</strong></p>
<h2>機構投資者對 Neurogene 的看法</h2>
<p>一些機構投資者和對沖基金最近調整了對該股票的持有。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Neurogene 的持股增加了 17.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 6,983 股該公司的股票，價值 82,000 美元，此前在上個季度購買了 1,059 股。Jennison Associates LLC 在第二季度將其在 Neurogene 的持股增加了 55.0%。Jennison Associates LLC 目前擁有 167,563 股該公司的股票，價值 2,505,000 美元，此前在此期間購買了 59,479 股。PNC Financial Services Group Inc. 在第二季度將其在 Neurogene 的持股增加了 43.6%。PNC Financial Services Group Inc. 目前擁有 4,055 股該公司的股票，價值 61,000 美元，此前在上個季度購買了 1,232 股。施羅德投資管理集團在第二季度獲得了對 Neurogene 的新頭寸，價值約為 451,000 美元。最後，美國銀行（Bank of America Corp DE）在第二季度將其在 Neurogene 的持股增加了 81.6%。美國銀行（Bank of America Corp DE）目前擁有 95,401 股該公司的股票，價值 1,426,000 美元，此前在此期間收購了 42,880 股。52.37% 的股票由機構投資者和對沖基金持有。</p>
<h2>Neurogene 價格表現</h2>
<p>NASDAQ:NGNE 的股票週一開盤價為 17.55 美元。該股票的市值為 2.7185 億美元，市盈率為-4.27，貝塔值為 1.60。Neurogene 的 12 個月低點為 6.88 美元，12 個月高點為 37.27 美元。該股票的 50 日移動平均價格為 20.76 美元，200 日移動平均價格為 22.12 美元。</p>
<p>Neurogene（納斯達克代碼：NGNE - 獲取免費報告）最近於 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為（0.99 美元），超出分析師的共識預期（1.26 美元）0.27 美元。平均而言，賣方分析師預計 Neurogene 本年度將發佈-4.27 的每股收益。</p>
<h2>關於 Neurogene</h2>
<p>（獲取免費報告）</p>
<p>Neurogene, Inc 是一家臨牀階段的生物技術公司，專注於開發針對罕見神經疾病的基因療法。該公司的主要平台採用腺相關病毒（AAV）載體，旨在將功能性疾病基因的拷貝直接傳遞到中樞神經系統。Neurogene 的產品線專注於遺傳性溶酶體儲存疾病，包括針對 GM1 和 GM2 神經節苷脂症的研究項目，以及針對其他單基因神經退行性疾病的額外前臨牀努力。</p>
<p>Neurogene 的專有 AAV9 基於遞送系統經過工程設計，能夠跨越血腦屏障，旨在提供在受影響組織中的持久基因表達。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Neurogene 更好</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>行政命令 14330：特朗普最大的舉措</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Neurogene 嗎？</h2>
<p>在您考慮 Neurogene 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Neurogene 並不在名單上。</p>
<p>雖然 Neurogene 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NGNE

<p>Neurogene Inc.（納斯達克代碼：NGNE）獲得了分析師的 “持有” 共識評級，其中包括一項賣出、兩項持有和四項買入建議。平均目標價格為 42.50 美元。機構投資者增加了持股比例，持有該股票的比例為 52.37%。該股票開盤價為 17.55 美元，市值為 2.7185 億美元，市盈率為-4.27。Neurogene 專注於罕見神經疾病的基因療法，重點關注遺傳性溶酶體儲存疾病</p>

<p>Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $42.50.</p>
<div class="lb-trans"><p>Neurogene Inc.（納斯達克代碼：NGNE - 獲取免費報告）在覆蓋該股票的七家評級公司中獲得了 “持有” 的共識評級，Marketbeat 報道。一位股票研究分析師對該股票給予了賣出建議，兩位給予了持有建議，四位給予了買入建議。在過去一年中，給予該股票評級的經紀人平均目標價為 42.50 美元。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
</div><p>NGNE has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $70.00 target price on shares of Neurogene in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Neurogene from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, December 13th.</p>
<div class="lb-trans"><p>NGNE 一直是多份研究分析師報告的主題。HC Wainwright 在 1 月 13 日的報告中重申了 “買入” 評級，並將 Neurogene 的目標價設定為 70.00 美元。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Neurogene 的 “賣出（d-）” 評級。最後，華爾街禪在 12 月 13 日的研究報告中將 Neurogene 的評級從 “持有” 下調至 “賣出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on Neurogene</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Neurogene 的最新股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Neurogene</h2>
<div class="lb-trans"><h2>機構投資者對 Neurogene 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Jennison Associates LLC raised its holdings in Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company's stock worth $2,505,000 after buying an additional 59,479 shares during the period. PNC Financial Services Group Inc. lifted its stake in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Schroder Investment Management Group acquired a new position in shares of Neurogene in the second quarter worth about $451,000. Finally, Bank of America Corp DE raised its holdings in shares of Neurogene by 81.6% during the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock valued at $1,426,000 after acquiring an additional 42,880 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近調整了對該股票的持有。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Neurogene 的持股增加了 17.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 6,983 股該公司的股票，價值 82,000 美元，此前在上個季度購買了 1,059 股。Jennison Associates LLC 在第二季度將其在 Neurogene 的持股增加了 55.0%。Jennison Associates LLC 目前擁有 167,563 股該公司的股票，價值 2,505,000 美元，此前在此期間購買了 59,479 股。PNC Financial Services Group Inc. 在第二季度將其在 Neurogene 的持股增加了 43.6%。PNC Financial Services Group Inc. 目前擁有 4,055 股該公司的股票，價值 61,000 美元，此前在上個季度購買了 1,232 股。施羅德投資管理集團在第二季度獲得了對 Neurogene 的新頭寸，價值約為 451,000 美元。最後，美國銀行（Bank of America Corp DE）在第二季度將其在 Neurogene 的持股增加了 81.6%。美國銀行（Bank of America Corp DE）目前擁有 95,401 股該公司的股票，價值 1,426,000 美元，此前在此期間收購了 42,880 股。52.37% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Neurogene Price Performance</h2>
<div class="lb-trans"><h2>Neurogene 價格表現</h2>
</div><p>Shares of NASDAQ:NGNE opened at $17.55 on Monday. The stock has a market cap of $271.85 million, a price-to-earnings ratio of -4.27 and a beta of 1.60. Neurogene has a 12 month low of $6.88 and a 12 month high of $37.27. The stock's 50 day moving average price is $20.76 and its 200 day moving average price is $22.12.</p>
<div class="lb-trans"><p>NASDAQ:NGNE 的股票週一開盤價為 17.55 美元。該股票的市值為 2.7185 億美元，市盈率為-4.27，貝塔值為 1.60。Neurogene 的 12 個月低點為 6.88 美元，12 個月高點為 37.27 美元。該股票的 50 日移動平均價格為 20.76 美元，200 日移動平均價格為 22.12 美元。</p>
</div><p>Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.27. On average, sell-side analysts expect that Neurogene will post -4.27 EPS for the current year.</p>
<div class="lb-trans"><p>Neurogene（納斯達克代碼：NGNE - 獲取免費報告）最近於 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為（0.99 美元），超出分析師的共識預期（1.26 美元）0.27 美元。平均而言，賣方分析師預計 Neurogene 本年度將發佈-4.27 的每股收益。</p>
</div><h2>About Neurogene</h2>
<div class="lb-trans"><h2>關於 Neurogene</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.</p>
<div class="lb-trans"><p>Neurogene, Inc 是一家臨牀階段的生物技術公司，專注於開發針對罕見神經疾病的基因療法。該公司的主要平台採用腺相關病毒（AAV）載體，旨在將功能性疾病基因的拷貝直接傳遞到中樞神經系統。Neurogene 的產品線專注於遺傳性溶酶體儲存疾病，包括針對 GM1 和 GM2 神經節苷脂症的研究項目，以及針對其他單基因神經退行性疾病的額外前臨牀努力。</p>
</div><p>Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.</p>
<div class="lb-trans"><p>Neurogene 的專有 AAV9 基於遞送系統經過工程設計，能夠跨越血腦屏障，旨在提供在受影響組織中的持久基因表達。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Neurogene</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Neurogene 更好</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>行政命令 14330：特朗普最大的舉措</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NGNE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neurogene Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Neurogene 嗎？</h2>
</div><p>Before you consider Neurogene, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Neurogene 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Neurogene 並不在名單上。</p>
</div><p>While Neurogene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Neurogene 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Neurogene Inc.（NASDAQ:NGNE）被分析師平均建議為 “持有”